Array Biopharma: (NASD: ARRY)

$5.89

0.20 (3.52%)

Volume 912,437

May 17 04:00 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		5.73 - 5.91
	
		52wk Low - High
		3.00 - 6.56
	
		Previous Close
		5.69
	
		Avg. Volume
		1,410,443
	
		Industry
		MED-BIOMED/GENE
	
		Market Cap
		687.13 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		1.61
	
		PE (Forward)
		0.00
	
		Current Year Est.
		-0.55
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		91 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/6/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            NA
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            -0.55
                        
                            Current Quarter Estimate
                            -0.13
                        
                            Most Accurate Estimate
                            -0.13
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            08-12-2013
                        
                            EPS Last Year
                            -0.51
                        
                            Expected Earnings Growth
                            NA
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. The company's proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas.   
Full ARRY Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
ARRY Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (06/2013)	Next Year (06/2014)
Average Estimate	-0.13	-0.15	-0.55	-0.45
Number of Estimates	5	1	7	6
Low Estimate	-0.15	-0.15	-0.57	-0.62
High Estimate	-0.12	-0.15	-0.54	NA
Year Ago EPS	-0.09	-0.13	-0.33	-0.55
EPS Growth	-46.67%	-15.38%	-67.53%	19.51%

More ARRY Estimates

Average Earnings Estimates for ARRY

EPS Growth for ARRY

Industry Analysis

Name	Symbol	Previous Close
ARRAY BIOPHARMA	ARRY	5.89
AETERNA ZENTARS	AEZS	2.10
ANIKA THERAPEUT	ANIK	14.40
GENTIUM SPA-ADR	GENT	8.87
AASTROM BIOSCI	ASTM	0.57
ACHILLION PHARM	ACHN	7.77
ADDEX THERA LTD	ADDXF	6.94
AFFYMAX INC	AFFY	1.33
ALEXION PHARMA	ALXN	102.90
ALKERMES INC	ALKS	31.69

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Zacks Commentary

Array Presents ARRY-520 Data

Apr 10, 2013

Gilead Seeks FDA Approval

Apr 09, 2013

Regeneron Aims HQ Expansion

Apr 08, 2013

BMY Announces Management Changes

Apr 08, 2013

R&D and Iclusig Update from Ariad

Apr 05, 2013

Orphan Status for Insmed's Arikace

Apr 04, 2013

BioMarin Files CTA for BMN-190

Apr 03, 2013

BMRN Seeks US Approval of Vimizim

Apr 02, 2013

More ARRY Zacks Commentary

Financials

EPS TTM	-0.51
Sales	85
Net Income	-52
Price/Earnings	NA
Price/Book	NA
Price/Cash Flow	NA
Price/Sales	10.60

More ARRY Financials

News

Array Biopharma Earnings Review: 12 Days after Announcement Shares Up 1.6% (ARRY) - Financial News Network Online - Earnings Lookback

May 18, 2013

Array BioPharma reports higher Q3 net loss, provides annual outlook - Datamonitor

May 17, 2013

Buyers Accumulate Shares of Array Biopharma, Up 1.9% - Financial News Network Online - Market Movers

May 17, 2013

Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting - Pr Newswire

May 15, 2013

Buyers Accumulate Shares of Array Biopharma, Up 2.9% - Financial News Network Online - Market Movers

May 14, 2013

Bottom 5 Companies in the Biotechnology Industry with the Lowest Relative Performance (SNTA, ARRY, INFI, CLDX, SGMO) - Financial News Network Online - News Corner

May 10, 2013

Stock Investors Bid Up Shares of Array Biopharma, Up 2.5% - Financial News Network Online - Market Movers

May 10, 2013

Synta Pharmaceuticals has Relatively Underperformed its Peers in the Biotechnology Industry (SNTA, ARRY, INFI, CLDX, SGMO) - Financial News Network Online - News Corner

May 9, 2013

See All News Stories on ARRY

Broker Recommendations

Current ABR	1.25
ABR (Last Week)	1.25
# of recs in ABR	8
Average Target Price	6.42
Industry Rank by ABR	91 out of 265
Rank in Industry	36 out of 155

More ARRY Broker Recommendations

Day Low - High	5.73 - 5.91
52wk Low - High	3.00 - 6.56
Previous Close	5.69
Avg. Volume	1,410,443
Industry	MED-BIOMED/GENE
Market Cap	687.13 M
Div - Yield	0.00 - 0.00
Beta	1.61
PE (Forward)	0.00
Current Year Est.	-0.55
Quarterly Earnings ESP	0.00%

PE (Forward)	NA
PEG Ratio	NA
Current Year Est.	-0.55
Current Quarter Estimate	-0.13
Most Accurate Estimate	-0.13
Earnings ESP	0.00%
Next Earnings Report Date	08-12-2013
EPS Last Year	-0.51
Expected Earnings Growth	NA

Username: Password:

Remember me [?]

Array Biopharma: (NASD: ARRY)

$5.89

0.20 (3.52%)

Volume 912,437

May 17 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description